[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"small-for-size-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:small-for-size-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100616995","phase-1-safety-and-tolerability-study-of-a-novel-bioartificial-liver-in-liver-failure-and-small-for-size-syndrome-100616995",false,"NCT07312864","Safety and Tolerability Study of a Novel Bioartificial Liver in Liver Failure and Small-for-Size Syndrome","A Clinical Trial Assessing the Safety, Tolerability, and Exploratory Efficacy of a Novel Bioartificial Liver Therapy in Patients With Liver Failure or Small-for-Size Syndrome","Inclusion Criteria:\n\n* Patients diagnosed with liver failure (including acute, subacute\u002Facute-on-chronic, and chronic liver failure) or small-for-size syndrome\n\nExclusion Criteria:\n\n* Presence of severe extrahepatic systemic end-stage diseases\n* Uncontrollable infection or active bleeding\n* Pregnant or breastfeeding women\n* History of allergy or known severe hypersensitivity to CiPSC-derived cell products or blood products\n* Peripheral vascular collapse leading to inability to obtain venous access or collect blood\n* Unable or unwilling to provide informed consent or unable to comply with study requirements\n* Unwilling to receive CiPSC-based therapy","ALL",{"count":18,"type":19},12,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE1","PHASE2","The goal of this clinical trial is to evaluate the safety and tolerability of a novel bioartificial liver (CiPS-BAL) in patients with liver failure or small-for-size syndrome. The study will also collect preliminary data on clinical outcomes and laboratory parameters during treatment. The main questions it aims to answer are:\n\nIs the novel bioartificial liver system safe and well tolerated in patients with liver failure or small-for-size syndrome?\n\nWhat effects does the treatment have on liver function and other clinical and laboratory indicators?\n\nResearchers will treat participants with the CiPS-BAL system, which uses hepatocytes derived from chemically induced pluripotent stem cells (CiPS) within a bioartificial liver device.",[26,27],"Liver Failure","Small-for-Size Syndrome","RECRUITING","2026-04-15",{"date":31,"type":32},"2026-04-20","ACTUAL",{"date":34,"type":32},"2025-12-01",{"date":36,"type":19},"2028-12-31",{"name":38,"class":39},"Beijing Friendship Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":40},"100590970","phase-4-octreotide-vs-splenic-artery-ligation-for-portal-flow-modulation-in-living-donor-liver-transplants-scalop-trial-100590970","NCT06974344","Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)","Randomized Controlled Trial Protocol Comparing Splenic Artery Ligation Versus Octreotide for Portal Flow Modulation (SCALOP) in Living Donor Liver Transplantation","SCALOP","Inclusion Criteria:\n\n1. Age ≥ 18 and \\\u003C70 years\n2. Male and female genders\n3. Undergoing Living Donor Liver Transplant (LDLT)\n4. All indications\n5. Receiving a small-for-size graft requiring portal flow modulation\n6. Informed consent provided.\n\nExclusion Criteria:\n\n1. Deceased Donor Liver Transplantation (DDLT)\n2. Dual LDLT or dual LDLT\u002FDDLT\n3. Pregnancy\n4. Known allergy to Octreotide \u002F Somatostatin analogue","18 Years","70 Years",{"count":52,"type":19},80,[54],"PHASE4","The goal of this clinical trial is to compare two treatments for regulating blood flow in small liver grafts during living donor liver transplantation (LDLT). The main questions it aims to answer are:\n\n* Is octreotide (a medication) as effective or better than splenic artery ligation (surgery) in reducing complications after transplantation?\n* Which treatment better controls blood flow while causing fewer side effects?\n\nResearchers will compare octreotide (given through an IV) to splenic artery ligation (performed during surgery) to see which approach works best for patients receiving small liver grafts.\n\nParticipants will:\n\n* Be randomly assigned to receive either octreotide or splenic artery ligation during their transplant surgery\n* Have their liver blood flow monitored closely during and after surgery\n\nBe followed for 90 days and 1 year to track complications, hospital stay, recovery, and survival.\n\nThis study may help doctors choose safer, more effective treatments for patients needing small liver grafts.",[27],[58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,27,75,76],"Living Donor Liver Transplantation","LDLT","Small-for-Size Graft","SFS","Portal Flow Modulation","Graft Inflow Modulation","Octreotide","Somatostatin Analogue","Splenic Artery Ligation,","SAL","Randomized Controlled Trial","RCT","Complications","Outcomes","Mortality","Liver Hemodynamics","Early Allograft Dysfunction","SFSS","Survival","NOT_YET_RECRUITING","2025-05-08",{"date":80,"type":32},"2025-05-15",{"date":82,"type":19},"2025-06-01",{"date":84,"type":19},"2030-09-01",{"name":86,"class":39},"King Faisal Specialist Hospital & Research Center"]